TCM
CLDX icon

Tekla Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Tekla Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-33,893
Closed -$6.59M – 101
2014
Q3 		$6.59M Buy
+33,893
New +$7.38M 0.31% 69

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Tekla Capital Management's CLDX Position: Q3 2021 in Review

Tekla Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2021, closing a stake of 7,053 shares — an estimated $236K sold.

Tekla Capital Management first reported a position in CLDX in Q3 2014 and held it in 25 quarters. The position peaked at $6.59M in Q3 2014. 160 funds tracked by Wall St. Rank hold CLDX as of Q3 2021.

  • Tekla Capital Management reported no remaining Celldex Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 7,053 Celldex Therapeutics shares in Q3 2021, an estimated $236K.
  • Tekla Capital Management first reported a position in Celldex Therapeutics in Q3 2014 and held it in 25 quarters.
  • Tekla Capital Management's Celldex Therapeutics position peaked at $6.59M in Q3 2014.
  • 160 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.